Drug intelligence / Profile preview

pasiniazid

Development stage
Phase 4
Lead developer
Lucane Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

**Pasiniazid** is a defined 1:1 molecular salt/complex of isoniazid and para-aminosalicylic acid used as an oral antitubercular drug. It dissociates in the gastrointestinal tract to deliver isoniazid, which is activated by mycobacterial catalase-peroxidase KatG and inhibits InhA-dependent mycolic-acid synthesis, and para-aminosalicylic acid, an antifolate prodrug whose active metabolites inhibit mycobacterial dihydrofolate reductase. It has been used in multidrug regimens for pulmonary tuberculosis, including retreatment regimens. ([medchemexpress.com](https://www.medchemexpress.com/Pasiniazid.html))

Brand names
DipasicFintozidJieheqingNidrapasParasal INHPascidaberPAS-HidracidaPashain
Other names
4-amino-2-hydroxybenzoic acid;pyridine-4-carbohydrazideIsoniazid 4-aminosalicylateIsoniazid4-aminosalicylateIsoniazid-4-aminosalicylateisoniazid aminosalicylateIsoniazid p-aminosalicylateIsonicotinic acid hydrazide 4-aminosalicylateIsonicotinic acid hydrazide p-aminosalicylateIsonicotinohydrazide 4-amino-2-hydroxybenzoateIsonicotinohydrazide4-amino-2-hydroxybenzoateIsonicotinohydrazide-4-amino-2-hydroxybenzoateParaniazidep-aminosalicylic acid isonicotinyl hydrazidePasiniazidaPasiniazidePasiniazidum
02

Targets

InhAKatGDHFR (Dihydrofolate reductase)NAT (Arylamine N-acetyltransferase 2)DHPS (Dihydropteroate synthase)

Beyond the preview

Go deeper on pasiniazid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pasiniazid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call